Mason Michael

SEC source: 0000950170-24-104031 · ownership.xml · nonDerivative · entry 1

Mason Michael · CIK 0001514291 · EVP, CFO & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 391,054

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-24-069860 · ownership.xml · nonDerivative · entry 1

Mason Michael · CIK 0001514291 · EVP, CFO & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 398,104

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-24-025191 · ownership.xml · nonDerivative · entry 2

Mason Michael · CIK 0001514291 · EVP, CFO & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 398,756

F3 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of performance-based restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-24-025191 · ownership.xml · nonDerivative · entry 1

Mason Michael · CIK 0001514291 · EVP, CFO & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 404,918

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $1.12 to $1.18, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0000950170-24-023292 · ownership.xml · nonDerivative · entry 2

Mason Michael · CIK 0001514291 · EVP, CFO & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 432,605

F2 · shares: Represents the award of RSUs pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2025.

SEC source: 0000950170-24-023292 · ownership.xml · nonDerivative · entry 1

Mason Michael · CIK 0001514291 · EVP, CFO & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 244,400

F1 · shares: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units ("RSUs"). The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-24-012832 · ownership.xml · nonDerivative · entry 1

Mason Michael · CIK 0001514291 · EVP, CFO & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 246,945

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-24-007588 · ownership.xml · nonDerivative · entry 1

Mason Michael · CIK 0001514291 · EVP, CFO & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 251,150

F1 · shares: Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2023 that have been earned based on the level of achievement of a certain clinical milestone, as certified by the issuer's compensation committee on January 24, 2024. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs will vest on February 28, 2024, the first anniversary of the grant date, subject to continued employment through such vesting date.

SEC source: 0001209191-23-048162 · doc4.xml · nonDerivative · entry 1

Mason Michael · CIK 0001514291 · EVP, CFO & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 237,817

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0001209191-23-034262 · doc4.xml · nonDerivative · entry 1

Mason Michael · CIK 0001514291 · EVP, CFO & Treasurer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 244,730

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0001209191-23-014843 · doc4.xml · nonDerivative · entry 2

Mason Michael · CIK 0001514291 · EVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 245,361

F2 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

SEC source: 0001209191-23-014843 · doc4.xml · nonDerivative · entry 1

Mason Michael · CIK 0001514291 · EVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 256,566

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2024.

SEC source: 0001209191-23-014078 · doc4.xml · nonDerivative · entry 1

Mason Michael · CIK 0001514291 · EVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 161,566

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

SEC source: 0001209191-23-007775 · doc4.xml · nonDerivative · entry 1

Mason Michael · CIK 0001514291 · EVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 164,368

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

SEC source: 0001209191-22-048394 · doc4.xml · derivative · entry 2

Mason Michael · CIK 0001514291 · EVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2032-08-30

F2 · derivative.exercise_date: This option was granted on August 31, 2022 pursuant to the Plan. The shares underlying this option vest as to 50% of the shares on August 31, 2023, with the remaining 50% vesting on August 31, 2024.

SEC source: 0001209191-22-048394 · doc4.xml · nonDerivative · entry 1

Mason Michael · CIK 0001514291 · EVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 168,509

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as to 50% of the shares on August 31, 2023, with the remaining 50% vesting on August 31, 2024.

SEC source: 0000899243-22-021234 · doc4.xml · nonDerivative · entry 2

Mason Michael · CIK 0001514291 · EVP, CFO, Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 138,509

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

SEC source: 0000899243-22-021234 · doc4.xml · nonDerivative · entry 1

Mason Michael · CIK 0001514291 · EVP, CFO, Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 138,512

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

SEC source: 0001209191-22-014628 · doc4.xml · derivative · entry 3

Mason Michael · CIK 0001514291 · EVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,600

Underlying: Common Stock · 111,600 shares

Expires 2032-02-27

F4 · derivative.exercise_date: This option was granted on February 28, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-22-014628 · doc4.xml · nonDerivative · entry 2

Mason Michael · CIK 0001514291 · EVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 139,110

F2 · shares: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.24 to $10.35, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-22-014628 · doc4.xml · nonDerivative · entry 1

Mason Michael · CIK 0001514291 · EVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 141,508

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023.

SEC source: 0001209191-22-008126 · doc4.xml · nonDerivative · entry 1

Mason Michael · CIK 0001514291 · EVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,308

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 7, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

SEC source: 0000899243-21-021368 · doc4.xml · derivative · entry 2

Mason Michael · CIK 0001514291 · EVP, CFO, Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-05-31

F2 · derivative.exercise_date: This option was granted on June 1, 2021 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on June 1, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0000899243-21-021368 · doc4.xml · nonDerivative · entry 1

Mason Michael · CIK 0001514291 · EVP, CFO, Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,255

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning June 1, 2022.

SEC source: 0001209191-21-015486 · doc4.xml · derivative · entry 2

Mason Michael · CIK 0001514291 · SVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,968

Underlying: Common Stock · 59,968 shares

Expires 2031-02-24

F3 · derivative.exercise_date: This option was granted on February 25, 2021 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 25, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-015486 · doc4.xml · nonDerivative · entry 1

Mason Michael · CIK 0001514291 · SVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,755

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 25, 2022.

F2 · balance_after: The reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 22,013 newly awarded RSUs, 24,450 RSUs previously reported in Table II, and 5,292 shares of common stock.

SEC source: 0001209191-21-011488 · doc4.xml · nonDerivative · entry 1

Mason Michael · CIK 0001514291 · SVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,292

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 11, 2021 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

SEC source: 0001209191-21-009076 · doc4.xml · derivative · entry 2

Mason Michael · CIK 0001514291 · SVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,450

Underlying: Common Stock · 8,150 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

F2 · derivative.exercise_date: On February 5, 2020, the reporting person was granted 32,600 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 5, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.

F2 · derivative.expiration_date: On February 5, 2020, the reporting person was granted 32,600 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 5, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.

SEC source: 0001209191-21-009076 · doc4.xml · nonDerivative · entry 1

Mason Michael · CIK 0001514291 · SVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,150

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

SEC source: 0001209191-20-007508 · doc4.xml · derivative · entry 2

Mason Michael · CIK 0001514291 · SVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,600

Underlying: Common Stock · 32,600 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 5, 2021, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 5, 2021, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date.

SEC source: 0001209191-20-007508 · doc4.xml · derivative · entry 1

Mason Michael · CIK 0001514291 · SVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,600

Underlying: Common Stock · 87,600 shares

Expires 2030-02-04

F1 · derivative.exercise_date: This option was granted on February 5, 2020. The shares underlying this option vest as to 25% of the shares on February 5, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-19-013078 · doc4.xml · derivative · entry 1

Mason Michael · CIK 0001514291 · SVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2029-02-24

F1 · derivative.exercise_date: This option was granted on February 25, 2019. The shares underlying this option vest as to 25% of the shares on February 25, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001735276-18-000072 · edgardoc.xml · derivative · entry 2

Mason Michael · CIK 0001514291 · VP, Finance and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,775

Underlying: Common Stock · 1,387 shares

Expires 2026-12-20

F2 · kind: On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. Effective September 27, 2018, the compensation committee of the Company determined the second performance criterion had been met and the option vested as to one-quarter of the shares.

SEC source: 0001735276-18-000072 · edgardoc.xml · derivative · entry 1

Mason Michael · CIK 0001514291 · VP, Finance and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,400

Underlying: Common Stock · 1,800 shares

Expires 2025-12-18

F1 · kind: On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development and regulatory events, as approved by our compensation committee. Effective September 27, 2018, the compensation committee of the Company determined the third performance criterion had been met and the option vested as to one-quarter of the shares.

SEC source: 0001735276-18-000058 · edgardoc.xml · derivative · entry 1

Mason Michael · CIK 0001514291 · VP, Finance and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,600

Underlying: Common Stock · 1,800 shares

Expires 2025-12-18

F1 · kind: On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development or commercial events, as approved by our compensation committee. Effective August 21, 2018, the compensation committee of the Company determined the second performance criterion had been met and the option vested as to one-quarter of the shares.

SEC source: 0001735276-18-000049 · edgardoc.xml · nonDerivative · entry 2

Mason Michael · CIK 0001514291 · VP, Finance and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 563

SEC source: 0001735276-18-000049 · edgardoc.xml · nonDerivative · entry 1

Mason Michael · CIK 0001514291 · VP, Finance and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,012

F1 · kind: On January 4, 2016, the reporting person was granted a restricted stock unit (RSU) to purchase shares of ALNY common stock. The shares subject to release vest upon the commercial launch of Alnylams first internally developed product, as approved by our compensation committee. Effective August 13, 2018, the compensation committee of the Company determined the performance criterion has been met and the RSU shares have vested.

SEC source: 0001735276-18-000049 · edgardoc.xml · derivative · entry 7

Mason Michael · CIK 0001514291 · VP, Finance and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,750

Underlying: Common Stock · 2,750 shares

Expires 2024-12-17

F4 · kind: On December 17, 2014, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective August 10, 2018, the compensation committee of the Company determined the final performance criteria had been met and the option vested as to the final third of the award.

SEC source: 0001735276-18-000049 · edgardoc.xml · derivative · entry 6

Mason Michael · CIK 0001514291 · VP, Finance and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,666

Underlying: Common Stock · 1,666 shares

Expires 2023-12-18

F3 · kind: On December 18, 2013, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective August 10, 2018, the compensation committee of the Company determined the final performance criteria had been met and the option will vest as to the final third of the award.

SEC source: 0001735276-18-000049 · edgardoc.xml · nonDerivative · entry 5

Mason Michael · CIK 0001514291 · VP, Finance and Treasurer

10b5-1 filing: Not disclosed

Ownership: Indirect · by Managed Account

Disclosed balance after: 276

F2 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.

F2 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.

F2 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.

SEC source: 0001735276-18-000049 · edgardoc.xml · nonDerivative · entry 4

Mason Michael · CIK 0001514291 · VP, Finance and Treasurer

10b5-1 filing: Not disclosed

Ownership: Indirect · by Managed Account

Disclosed balance after: 253

F2 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.

F2 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.

F2 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.

SEC source: 0001553878-18-000013 · edgardoc.xml · derivative · entry 1

Mason Michael · CIK 0001514291 · VP, Finance and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,000

Underlying: Common Stock · 4,000 shares

Expires 2028-02-28

F1 · shares: Represents the time-vested portion of the reporting person's Annual Stock Option Award for 2017. The reporting person also received 4,000 options to purchase shares of ALNY common stock that will vest upon the achievement of three specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the option vests.

F2 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to the remaining shares ratably at the end of each three-month period thereafter over the following thirty-three (33) months

SEC source: 0001735276-18-000049 · edgardoc.xml · nonDerivative · entry 3

Mason Michael · CIK 0001514291 · VP, Finance and Treasurer

10b5-1 filing: Not disclosed

Ownership: Indirect · by Managed Account

Disclosed balance after: 231

F2 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.

F2 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.

F2 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.

SEC source: 0001325812-18-000004 · edgardoc.xml · derivative · entry 23

Mason Michael · CIK 0001514291 · VP, Finance and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2025-12-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017.

SEC source: 0001325812-18-000004 · edgardoc.xml · derivative · entry 22

Mason Michael · CIK 0001514291 · VP, Finance and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,063

Underlying: Common Stock · 6,187 shares

Expires 2024-12-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017.

F9 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.

SEC source: 0001325812-18-000004 · edgardoc.xml · derivative · entry 21

Mason Michael · CIK 0001514291 · VP, Finance and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,600

Underlying: Common Stock · 3,600 shares

Expires 2025-12-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017.

F9 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.

SEC source: 0001325812-18-000004 · edgardoc.xml · derivative · entry 20

Mason Michael · CIK 0001514291 · VP, Finance and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,439 shares

Expires 2023-12-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017.

F9 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.

SEC source: 0001325812-18-000004 · edgardoc.xml · derivative · entry 19

Mason Michael · CIK 0001514291 · VP, Finance and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,162

Underlying: Common Stock · 1,388 shares

Expires 2026-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017.

F9 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.

SEC source: 0001325812-18-000004 · edgardoc.xml · derivative · entry 18

Mason Michael · CIK 0001514291 · VP, Finance and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,750 shares

Expires 2024-12-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017.

SEC source: 0001325812-18-000004 · edgardoc.xml · derivative · entry 17

Mason Michael · CIK 0001514291 · VP, Finance and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,750

Underlying: Common Stock · 2,750 shares

Expires 2024-12-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017.